ClinicalTrials.gg
TerminatedNCT02060487AFFILIATEUpdated May 13, 2022Results posted

Effects of Oral Sildenafil on Mortality in Adults With PAH

A Phase 4 interventional study of sildenafil citrate and sildenafil citrate in Pulmonary Arterial Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 82 sites in 23 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-05-13.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
Study was terminated by Sponsor at recommendation of Data Monitoring Committee after completion of first interim analysis as primary objective was met.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
385
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.

Enrollment
Largest of 18
385 · median 23
Started
2014
the only one that year
Phase 4
6 of 18
none open now
Registered
16th of 18
by date
Lead sponsor
7 of 18
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one has the largest enrollment, is the only one that started in 2014, is one of 6 in phase 4, and was the 16th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sildenafil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day [TID]). In addition, the relative effects on clinical worsening and 6-minute walking distance (6MWD) will be assessed.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • pulmonary arterial hypertension
  • pulmonary hypertension
  • PAH
  • sildenafil
  • revatio
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects ≥ 18 \<75 years of age with any of the following conditions:

  • Idiopathic Primary Pulmonary Arterial Hypertension (IPAH)
  • PAH secondary to connective tissue disease
  • PAH with surgical repair (at least 5 years previously) of atrial septal defect (ASD),ventricular septal defect (VSD), patent ductus arteriosus (PDA) and aorto-pulmonary window
  • PAH diagnosis confirmed by right heart catheterization performed within 12 months prior to randomization
  • Functional Class II-IV; Baseline 6MWD ≥ 50 m.

Exclusion criteria

Exclusion Criteria:

  • Significant (ie, >2+) valvular disease other than tricuspid regurgitation or pulmonary regurgitation
  • History of cardiac arrest, respiratory arrest, hemodynamic collapse, CPR, ventricular tachycardia, ventricular fibrillation, or uncontrolled atrial fibrillation
  • History of pulmonary embolism; History of chronic lung disease / restrictive lung disease (eg, (COPD) or scleroderma) with impairment of lung function
  • No prior long term treatment with PDE-5 inhibitors
  • Treatment with bosentan OR riociguat within 3 months of randomization
  • Current treatment with nitrates or nitric oxide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
385 participants (actual)

Study arms

  • Experimental
    Low dose

    Drug: sildenafil citrate

  • Experimental
    Medium dose

    Drug: sildenafil citrate

  • Experimental
    High dose

    Drug: sildenafil citrate

Interventions

  • sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study

    Also known as: Revatio

  • sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study

    Also known as: Revatio

  • sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study

    Also known as: Revatio

06

What researchers measure

Primary outcomes

  1. Overall Survival

    In this outcome measure number of deaths during the study were reported.

    Time frame: Day 1 of study treatment up to date of death (within a maximum duration of 2102 days)

Secondary outcomes

  1. Number of Participants With Clinical Worsening Events

    Clinical worsening was defined as all-cause mortality, non-elective hospital stay for worsening pulmonary arterial hypertension (PAH) (including but not limited to right heart failure \[RHF\], initiation of intravenous (IV) prostanoids, lung transplantation, or septostomy) or disease progression. Disease progression was defined as a reduction from baseline in the 6-Minute Walk Distance (6MWD) test by 15% and worsening functional class from baseline, both confirmed by second test within 2 weeks of study treatment.

    Time frame: Day 1 of study treatment up to date of clinical worsening event (within a maximum duration of 2080 days)

  2. Change From Baseline in 6-Minute Walk Distance (6MWD) at Month 6

    6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Analysis was performed using mixed model for repeated measures (MMRM), adjusted for baseline 6MWD and for randomization stratification factors: PAH treatment at study entry and etiology of PAH.

    Time frame: Baseline, Month 6

  3. Change From Baseline in 6-Minute Walk Distance (6MWD) at Month 12

    6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Analysis was performed using mixed model for repeated measures (MMRM), adjusted for baseline 6MWD and for randomization stratification factors: PAH treatment at study entry and etiology of PAH.

    Time frame: Baseline, Month 12

07

Results

Posted May 10, 2022
Limitations and caveats
Study was terminated by Sponsor at recommendation of Data Monitoring Committee after completion of first interim analysis as primary objective was met. For OS and clinical worsening(CW) endpoints, significance level was adjusted to allow for interim analysis. Hence 99.7% CIs were presented instead of 95% CIs. 80mg vs 5mg comparison for OS was primary and it was key secondary for CW. CIs for other dose comparisons for these endpoints were nominal. P-values and CIs for other endpoints were nominal

Participant flow

This was a randomized, double-blind, parallel-group, multinational and multicenter study to assess the effects of oral sildenafil on mortality in adult participants with pulmonary arterial hypertension (PAH). The study was conducted at 68 active sites in 23 countries.

Participant flow — Overall Study
MilestoneSildenafil 5 mgSildenafil 20 mgSildenafil 80 mg
Started129128128
Completed000
Not completed129128128
Withdrew: Other121
Withdrew: Lack of efficacy010
Withdrew: Withdrawal by subject3104
Withdrew: Study terminated by sponsor8789100
Withdrew: Randomized in error100
Withdrew: Protocol violation011
Withdrew: Lost to follow-up302
Withdrew: Death342519
Withdrew: Adverse event001

Outcome measures

PrimaryOverall Survival

In this outcome measure number of deaths during the study were reported.

Time frame:
Day 1 of study treatment up to date of death (within a maximum duration of 2102 days)
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsSildenafil 5 mgSildenafil 20 mgSildenafil 80 mg
Overall Survival342519
Statistical analysis
  • Sildenafil 5 mg vs Sildenafil 20 mg · Hazard ratio (hr): 0.68 · 99.7% CI 0.31 to 1.49Hazard ratio estimated from the Proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH.
  • Sildenafil 5 mg vs Sildenafil 80 mg · Hazard ratio (hr): 0.51 · 99.7% CI 0.22 to 1.21Hazard ratio estimated from the Proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH.
  • Sildenafil 20 mg vs Sildenafil 80 mg · Hazard ratio (hr): 0.74 · 99.7% CI 0.30 to 1.84Hazard ratio estimated from the Proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH.
SecondaryNumber of Participants With Clinical Worsening Events

Clinical worsening was defined as all-cause mortality, non-elective hospital stay for worsening pulmonary arterial hypertension (PAH) (including but not limited to right heart failure \[RHF\], initiation of intravenous (IV) prostanoids, lung transplantation, or septostomy) or disease progression. Disease progression was defined as a reduction from baseline in the 6-Minute Walk Distance (6MWD) test by 15% and worsening functional class from baseline, both confirmed by second test within 2 weeks of study treatment.

Time frame:
Day 1 of study treatment up to date of clinical worsening event (within a maximum duration of 2080 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Worsening Events
ParticipantsSildenafil 5 mgSildenafil 20 mgSildenafil 80 mg
Number of Participants With Clinical Worsening Events523628
Statistical analysis
  • Sildenafil 5 mg vs Sildenafil 20 mg · Wald test · p = 0.035 · Hazard ratio (hr): 0.63 · 99.7% CI 0.33 to 1.21Hazard ratio estimated from the Proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH.
  • Sildenafil 5 mg vs Sildenafil 80 mg · Wald test · p = <0.001 · Hazard ratio (hr): 0.44 · 99.7% CI 0.22 to 0.89Hazard ratio estimated from the Proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH.
  • Sildenafil 20 mg vs Sildenafil 80 mg · Wald test · p = 0.195 · Hazard ratio (hr): 0.72 · 99.7% CI 0.34 to 1.52Hazard ratio estimated from the Proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH.
SecondaryChange From Baseline in 6-Minute Walk Distance (6MWD) at Month 6

6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Analysis was performed using mixed model for repeated measures (MMRM), adjusted for baseline 6MWD and for randomization stratification factors: PAH treatment at study entry and etiology of PAH.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · Meters
Change From Baseline in 6-Minute Walk Distance (6MWD) at Month 6
MetersSildenafil 5 mgSildenafil 20 mgSildenafil 80 mg
Change From Baseline in 6-Minute Walk Distance (6MWD) at Month 612.2 (-0.67 to 25.16)27.3 (14.52 to 39.99)31.2 (18.68 to 43.66)
Statistical analysis
  • Sildenafil 5 mg vs Sildenafil 20 mg · MMRM · p = 0.0627 · Least-squares means difference: 15.0 · 95% CI -0.80 to 30.81
  • Sildenafil 5 mg vs Sildenafil 80 mg · MMRM · p = 0.0201 · Least-squares means difference: 18.9 · 95% CI 2.99 to 34.86
  • Sildenafil 20 mg vs Sildenafil 80 mg · MMRM · p = 0.6254 · Least-squares means difference: 3.9 · 95% CI -11.85 to 19.68
SecondaryChange From Baseline in 6-Minute Walk Distance (6MWD) at Month 12

6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Analysis was performed using mixed model for repeated measures (MMRM), adjusted for baseline 6MWD and for randomization stratification factors: PAH treatment at study entry and etiology of PAH.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · Meters
Change From Baseline in 6-Minute Walk Distance (6MWD) at Month 12
MetersSildenafil 5 mgSildenafil 20 mgSildenafil 80 mg
Change From Baseline in 6-Minute Walk Distance (6MWD) at Month 1214.3 (-0.58 to 29.27)35.7 (20.91 to 50.48)34.8 (20.21 to 49.43)
Statistical analysis
  • Sildenafil 5 mg vs Sildenafil 20 mg · MMRM · p = 0.0286 · Least-squares means difference: 21.3 · 95% CI 2.25 to 40.45
  • Sildenafil 5 mg vs Sildenafil 80 mg · MMRM · p = 0.0364 · Least-squares means difference: 20.5 · 95% CI 1.30 to 39.65
  • Sildenafil 20 mg vs Sildenafil 80 mg · MMRM · p = 0.9283 · Least-squares means difference: -0.9 · 95% CI -19.94 to 18.19

Adverse events

Collected over Baseline up to 28 days after last dose of study treatment (up to a maximum duration of 2108 days for sildenafil 5 mg; up to a maximum duration of 2012 days for sildenafil 20 mg; up to a maximum duration of 2101 days for sildenafil 80 mg). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sildenafil 5 mg34/129 (26.4%)66/129 (51.2%)108/129 (83.7%)
Sildenafil 20 mg25/128 (19.5%)49/128 (38.3%)107/128 (83.6%)
Sildenafil 80 mg19/128 (14.8%)51/128 (39.8%)111/128 (86.7%)
Most frequent serious events
Showing 10 of 167
Most frequent serious events
EventSildenafil 5 mgSildenafil 20 mgSildenafil 80 mg
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders17/12910/1288/128
Right ventricular failureCardiac disorders11/1294/1282/128
Cardiac failureCardiac disorders9/1298/1283/128
PneumoniaInfections and infestations7/1296/1283/128
DyspnoeaRespiratory, thoracic and mediastinal disorders3/1291/1284/128
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders2/1294/1282/128
Acute kidney injuryRenal and urinary disorders4/1291/1282/128
Cardiac arrestCardiac disorders1/1293/1280/128
Cardiac failure congestiveCardiac disorders3/1292/1283/128
AppendicitisInfections and infestations0/1291/1283/128
Most frequent other events
Showing 10 of 650
Most frequent other events
EventSildenafil 5 mgSildenafil 20 mgSildenafil 80 mg
HeadacheNervous system disorders26/12945/12833/128
DiarrhoeaGastrointestinal disorders13/12917/12820/128
NasopharyngitisInfections and infestations19/12916/12819/128
DizzinessNervous system disorders12/12915/12818/128
Oedema peripheralGeneral disorders14/12917/1288/128
DyspnoeaRespiratory, thoracic and mediastinal disorders12/12916/12811/128
NauseaGastrointestinal disorders16/12912/1288/128
Upper respiratory tract infectionInfections and infestations16/1298/12813/128
Back painMusculoskeletal and connective tissue disorders16/12910/12814/128
Chest painGeneral disorders7/12915/12813/128

Baseline characteristics

All randomized participants were included in the baseline analysis population.

Age, Continuous
Age, Continuous(Years)Sildenafil 5 mgSildenafil 20 mgSildenafil 80 mgTotal
Mean51.4 ± 15.0251.2 ± 15.8152.1 ± 14.7251.6 ± 15.16
Sex: Female, Male
Sex: Female, Male(Participants)Sildenafil 5 mgSildenafil 20 mgSildenafil 80 mgTotal
Female9710298297
Male32263088
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sildenafil 5 mgSildenafil 20 mgSildenafil 80 mgTotal
Hispanic or Latino54312
Not Hispanic or Latino124124125373
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sildenafil 5 mgSildenafil 20 mgSildenafil 80 mgTotal
American Indian or Alaska Native0000
Asian23141956
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White104113108325
More than one race0000
Unknown or Not Reported2114
08

Study locations

82 sites
  • Emory University Investigational Drug Services
    Atlanta, Georgia 30322, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Frederik Meijer Heart & Vascular Institute Cardiovascular Research
    Grand Rapids, Michigan 49503, United States
  • Spectrum Health Butterworth Hospital IDS Pharmacy
    Grand Rapids, Michigan 49503, United States
  • Spectrum Health Heart & Lung Specialized Care Clinic
    Grand Rapids, Michigan 49503, United States
  • Spectrum Health Hospitals
    Grand Rapids, Michigan 49503, United States
  • Spectrum Health Medical Group - Pulmonary Division
    Grand Rapids, Michigan 49546, United States
  • Spectrum Health
    Grand Rapids, Michigan 49546, United States
  • Robert V. Sibilia MD, Inc.
    Wooster, Ohio 44691, United States
  • UT Southwestern Medical School
    Dallas, Texas 75390-8550, United States
  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • St. Vincent's Hospital
    Darlinghurst, New South Wales 2010, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Royal Brisbane & Women's Hospital
    Herston, Queensland 4029, Australia
  • Australian Respiratory and Sleep Medicine Institute
    Bedford Park, South Australia 5042, Australia
  • University Hospital of Mont-Godinne
    Yvoir, 5530, Belgium
  • University Clinical Center of the Republic of Srpska
    Banja Luka, B&h/republic OF Srpska 78000, Bosnia and Herzegovina
  • Clinical Center University Sarajevo
    Sarajevo, Bosnia AND Herzegovina/canton Sarajevo 71000, Bosnia and Herzegovina
  • Health Institution Special Hospital "Medical Institute Bayer"
    Tuzla, Canton Tuzla 75000, Bosnia and Herzegovina
  • University Clinical Hospital Mostar
    Mostar, Herzegovina-neretva Canton 88000, Bosnia and Herzegovina
  • University Hospital Center Zagreb
    Zagreb, 10 000, Croatia
  • University Hospital Dubrava
    Zagreb, 10000, Croatia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, Czech Republic 128 08, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 779 00, Czechia
  • Institut Klinicke a Experimentalni Mediciny
    Praha 4, 140 21, Czechia
  • DRK Kliniken Berlin, Westend
    Berlin, 14050, Germany
  • Universitaetsklinikum der TU Dresden
    Dresden, 01307, Germany
  • Universitatsklinikum TU Dresden
    Dresden, 01307, Germany
  • Universitaetsmedizin Greifswald
    Greifswald, 17475, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Thoraxklinik am Universitaetsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Universitaetsklinikum Schleswig-Holstein
    Luebeck, 23538, Germany
  • University General Hospital of Athens "Attikon"
    Athens, Attiki 12462, Greece
  • University General Hospital of Alexandroupolis
    Alexandroupolis, Evros 68100, Greece
  • University General Hospital of Patras
    Patras, 26504, Greece
  • University General Hospital of Thessaloniki AHEPA
    Thessaloniki, 54636, Greece
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Prince of Wales Hospital
    Shatin, New Territories, Hong Kong
  • The Chaim Sheba Medical Center
    Tel-Hashomer, 5262000, Israel
  • Pauls Stradins Clinical University Hospital
    Riga, LV-1002, Latvia
  • Hospital Sultanah Aminah
    Johor Bahru, Johor 80100, Malaysia
  • Hospital Sultanah Bahiyah
    Alor Setar, Kedah 05460, Malaysia
  • Hospital Serdang
    Kajang, Selangor 43000, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Centro De Prevencion Y Rehabilitacion De Enfermedades Pulmonares Crónicas
    Monterrey, Nuevo LEÓN 64460, Mexico
  • Centro de Desarrollo Biomedico
    Merida, Yucatan 97070, Mexico
  • Centro de Estudios Clinicos de Queretaro S.C.
    Queretaro, 76000, Mexico
  • Samodzielny Publiczny Szpital Kliniczny nr 4
    Lublin, 20-954, Poland
  • Institutul Inimii ,,Niculae Stancioiu" Cluj Napoca
    Cluj-Napoca, 400001, Romania
  • Institutul de Urgenta pentru Boli Cardiovasculare si Transplant Targu-Mures
    Targu-Mures, 540136, Romania
  • FSBI "Research Institute of complex problems of cardiovascular diseases"
    Kemerovo, 650002, Russian Federation
  • FSBI Scientific Research Institute of Pulmonology of FMBA
    Moscow, 105077, Russian Federation
  • FSBI "E.Meshalkin National medical research center"
    Novosibirsk, 630055, Russian Federation
  • FSBI "V.A. Almazov National Medical Research Center"
    St. Petersburg, 197341, Russian Federation
  • Institute for Cardiovascular disease of Vojvodina
    Sremska Kamenica, Vojvodina 21204, Serbia
  • Institute for Pulmonary Diseases of Vojvodina
    Sremska Kamenica, Vojvodina 21204, Serbia
  • Clinical Center of Serbia
    Belgrade, 11000, Serbia
  • University Medical Center Zvezdara
    Belgrade, 11000, Serbia
  • Clinical Center Kragujevac
    Kragujevac, 34 000, Serbia
  • National University Heart Centre, National University Hospital Singapore (NUHS)
    Singapore, 119228, Singapore
  • Khoo Teck Puat Hospital
    Singapore, 768828, Singapore
  • Center of Chest Diseases
    Johannesburg, Gauteng 2193, South Africa
  • Dr PG Williams Practice
    Johannesburg, Gauteng 2193, South Africa
  • Hospital Universitario Vall d´Hebrón
    Barcelona, Cataluña 08035, Spain
  • Faculty of Medicine, Chulalongkorn University
    Pathumwan, Bangkok 10330, Thailand
  • King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University
    Pathumwan, Bangkok 10330, Thailand
  • Maharaj Nakorn Chiang Mai Hospital
    Muang, Chiang MAI 50200, Thailand
  • Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University
    Sripoom Sub-district, Muang, Chiang MAI 50200, Thailand
  • Division of Cardiology, Department of Medicine, Faculty of Medicine, Khon Kaen University
    Muang District, Khon Kaen 40002, Thailand
  • Queen Sirikit Heart Center of the Northeast, Khon Kaen University
    Muang District, Khon Kaen 40002, Thailand
  • Srinagarind Hospital, Faculty of Medicine, Khon Kaen University
    Muang District, Khon Kaen 40002, Thailand
  • Bakirkoy Dr. Sadi Konuk Training and Research Hospital
    Istanbul, Bakirkoy 34147, Turkey
  • Istanbul University Cerrahpasa Medical Faculty
    Istanbul, Fatih 34096, Turkey
  • Istanbul University Haseki Cardiology Institute
    Istanbul, Fatih 34096, Turkey
  • Dokuz Eylul Üniversitesi Tıp Fakültesi Kardiyoloji Bilim Dalı
    Izmir, Inciralti 35340, Turkey
  • Marmara University Pendik Training and Research Hospital
    Istanbul, Pendik 34899, Turkey
  • Komunalne nekomertsiine pidpryiemstvo
    Kharkiv,, 61176, Ukraine
  • Komunalne nekomertsiine pidpryiemstvo Oleksandrivska klinichna likarnia m. Kyieva
    Kyiv, 01601, Ukraine
  • Komunalne nekomertsiine pidpryiemstvo
    Kyiv, 03115, Ukraine
  • Derzhavna ustanova Natsionalnyi naukovyi tsentr
    Kyiv, 03680, Ukraine
  • Komunalne pidpryiemstvo "Dnipropetrovskyi oblasnyi klinichnyi tsentr kardiolohii ta kardiokhirurhii"
    M. Dnipro, 49044, Ukraine
  • Komunalne nekomertsiine pidpryiemstvo
    Uzhhorod,, 88000, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Feb 2021, 77 months.

Results were first posted in May 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2014
First posted
Feb 12, 2014
StartActual
Sep 22, 2014
Primary completionActual
Feb 26, 2021
CompletionActual
Feb 26, 2021
Results first posted
May 10, 2022
Last update
May 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02060487
Responsible party
Sponsor
First posted
Feb 12, 2014
Start date
Sep 22, 2014
Primary completion
Feb 26, 2021
Completion
Feb 26, 2021
Results posted
May 10, 2022
Last update
May 13, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion